Pharming Launches Joenja (leniolisib) in Japan for APDS Patients

Pharming has commercially launched Joenja (leniolisib) in Japan for adult and pediatric patients aged 4 and older with Activated PI3K Delta Syndrome (APDS). This follows the drug's listing on the Japan National Health Insurance drug price list and prior approval by the Ministry of Health, Labour and Welfare in March. The launch provides a new treatment option for patients with this rare primary immunodeficiency.